|Bid||263.00 x 200|
|Ask||279.00 x 200|
|Day's Range||269.09 - 275.51|
|52 Week Range||232.00 - 333.65|
|PE Ratio (TTM)||17.20|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In 2016, Biogen’s (BIIB) Tecfidera reported revenues of ~$4.0 billion, which reflected ~9% growth year-over-year (or YoY).
Currently, Biogen is conducting 13 clinical studies in early phases and expects promising results from those trials.
Since being launched in 2014 with financing from Fidelity and other prominent investors, Cambridge-based Scholar Rock has been developing a drug that is designed to block a protein that limits muscle growth. On Wednesday, the privately-held, 40-employee company revealed for the first time which disease it plans to target: spinal muscular atrophy, or SMA, a leading genetic cause of death in infants. There was no approved treatment for SMA until December 2016, when the FDA green-lighted Biogen's (BIIB) Spinraza.